Novartis Will Send Tislelizumab Application to Regulators for Esophageal Cancer

After pocketing positive phase 3 topline results, Novartis will ask regulators to approve its checkpoint inhibitor tislelizumab as first-line add-on therapy for patients with previously untreatable esophageal squamous-cell carcinoma (ESCC).
Source: Drug Industry Daily